A Single-Center, Randomized, Open-label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Vancomycin or Linezolid Versus Standard of Care Plus Vancomycin or Linezolid as Empiric Therapy in Febrile Neutropenic Adults With Cancer
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Cefepime; Linezolid; Meropenem; Piperacillin/tazobactam; Vancomycin
- Indications Febrile neutropenia
- Focus Therapeutic Use
- Sponsors Forest Laboratories
Most Recent Events
- 09 Sep 2016 Status changed from not yet recruiting to discontinued as the study is no longer aligned with the revised clinical development plan and commercial strategy
- 13 Apr 2016 New trial record